Introduction: spinal muscular atrophy
=====================================

Spinal muscular atrophy (SMA), which is characterized by degeneration of spinal cord lower motor neurons that leads to proximal muscle wasting and paralysis, is a common autosomal recessive disease affecting 1 in 6000 live births ([@b90-0040457]; [@b60-0040457]). The disease is classified into four types (Type I--IV) based on the age of onset and clinical symptoms. Although there is a wide spectrum of clinical severity, in its commonest and most severe form (Type I), SMA leads to death in infancy from respiratory muscle weakness. Even patients with non-fatal forms of SMA (Types III and IV) are considerably disabled and there is an urgent need for treatments that slow or arrest progression of the disease.

The complex molecular genetic basis of SMA raises challenges for modeling the disease in other species. Owing to an intrachromosomal duplication event on chromosome 5q13, humans possess two copies of the gene encoding 'survival motor neuron' (SMN) -- *SMN1* and *SMN2* ([@b60-0040457]). Deletion or gene conversion events render SMA patients homozygously null for *SMN1*, whereas they retain a variable number of *SMN2* copies. A critical C-to-T transition six base pairs into exon 7, present in all copies of the *SMN2* gene described in humans to date, causes aberrant splicing of 80--90% of *SMN2* transcripts, causing them to lack exon 7 (*SMNΔ7*) and therefore produce a protein product with reduced stability ([@b67-0040457]; [@b76-0040457]; [@b66-0040457]). SMN levels generally correlate with disease severity ([@b23-0040457]; [@b61-0040457]) and, because complete loss of SMN is lethal, SMA only arises as a disease in humans owing to the presence of *SMN2*, which provides sufficient residual full-length protein for cellular viability ([@b69-0040457]; [@b28-0040457]; [@b68-0040457]). SMA is therefore a disease of low levels of protein and not total ablation, a situation that any model system, either in vitro or in vivo, must reproduce in order to provide meaningful insights.

SMN is widely and constitutively expressed, and has been implicated in a range of cellular processes, of which small nuclear ribonucleoprotein (snRNP) assembly is currently the best characterized ([@b31-0040457]; [@b65-0040457]; [@b72-0040457]; [@b93-0040457]). Owing to the high degree of evolutionary conservation of the gene encoding SMN, the effects of SMN protein depletion have been modeled in diverse organisms, including in the invertebrates *Caenorhabditis elegans* ([@b14-0040457]; [@b110-0040457]) and *Drosophila melanogaster* ([@b19-0040457]; [@b20-0040457]), and the vertebrates *Danio rerio* ([@b71-0040457]; [@b11-0040457]) and *Mus musculus* ([@b43-0040457]; [@b77-0040457]; [@b59-0040457]). Zebrafish and the invertebrate models are well suited to large-scale screening of drug or genetic-knockdown libraries prior to mammalian validation ([@b118-0040457]; [@b25-0040457]; [@b109-0040457]). However, given that the essential elements of the organization of neuromuscular function are conserved across 50 million years of evolution between mice and humans, mouse models are probably best placed to answer fundamental questions about SMN biology in the nervous system and the pathogenesis of SMA.

Mouse models of SMA
===================

Mouse models not only allow the dissection of biological processes and assessment of gene and protein function in a mammalian context, but are a useful preclinical tool for testing potential therapies. Thus, an ideal mouse model of SMA should faithfully recapitulate the cellular levels of SMN protein seen in patients in order to preserve the relative selectivity for motor neuron degeneration. Levels that are too low, such as can be found in models involving tissue-specific ablation of SMN ([@b35-0040457]), simply induce cell death through disrupting the constitutive cellular function of SMN, providing limited insight into motor neuron vulnerability. The level of SMN expressed should also ideally be titrated to ensure that the mouse lives long enough for phenotypic analysis and therapeutic trials.

*SMN2* transgenic mice
----------------------

Mice possess a single *Smn* gene, which has 82% amino acid identity with its human homolog and a similar expression pattern ([@b8-0040457]; [@b24-0040457]; [@b114-0040457]). Homozygous *Smn* deletion results in massive embryonic cell death before implantation ([@b102-0040457]). Heterozygous null mice lack a marked clinical phenotype, although some reports suggest that there is histologically detectable age-dependent loss of neuromuscular integrity ([@b102-0040457]; [@b46-0040457]; [@b6-0040457]). A number of different strategies have been employed to produce models that recapitulate the human genotype (summarized in [Table 1](#t1-0040457){ref-type="table"}, with further information at <http://jaxmice.jax.org/list/ra1733.html>). Two groups showed that expression of a human *SMN2* transgene on the *Smn-*null background rescues lethality, and that transgene copy number modifies severity ([@b43-0040457]; [@b77-0040457]). Mice carrying one or two copies of *SMN2* (*Smn*^−/−^; *SMN2*^+/+^) are indistinguishable from controls at birth but die before postnatal day 7 (P7), and so are often referred to as the 'severe' model (and will be referred to as such in the remainder of this review article). Mice with four or more copies of *SMN2* show complete rescue and a normal lifespan, indicating that modestly enhanced expression of full-length SMN from the *SMN2* gene can prevent SMA, confirming the idea that enhancing *SMN2* expression is a potential therapeutic strategy.

Modifications to the severe *SMN2* mouse
----------------------------------------

Introduction of a second transgene, containing human *SMNΔ7* cDNA, into the severe model extends the lifespan from 6 to 13 days ([@b59-0040457]). Initially generated to assess potential SMNΔ7 toxicity ([@b54-0040457]), the 'SMNΔ7' model (*Smn*^−/−^; *SMN2*^+/+^; *SMNΔ7*^+/+^), which is still in effect a model of severe postnatal SMA, is thought to be milder owing to the formation of heterologous complexes between full-length SMN and SMNΔ7, which might stabilize SMN and affect its turnover. A number of other transgenes containing point mutations in *SMN1* (A2G, A111G) have also been introduced into the severe model, resulting in increased lifespan ([@b78-0040457]; [@b121-0040457]). However, unlike *SMN2*, which generates a small amount of full-length protein, none of the other transgenes rescue the embryonic lethality caused by *Smn* deletion, indicating that some full-length SMN is an absolute requirement for normal cellular function. Using a slightly different approach to reduce Smn levels, a knock-in allele that disturbs endogenous *Smn* splicing (*Smn*^*2B*/−^), similar to human *SMN2*, was shown to result in more moderate severity, with a few animals living longer than 1 month ([@b12-0040457]).

Cre-*loxP* models
-----------------

Targeting of genomic DNA using the Cre-*loxP* recombination system to perform deletion of *Smn* exon 7 from a conditional (floxed) allele (*Smn^F7^*) should theoretically result in the sole production of SmnΔ7 and complete absence of full-length Smn in the presence of Cre recombinase. Indeed, crossing these mice with tissue-specific Cre mouse lines effectively produces complete cellular knockdown of Smn in target tissues ([@b35-0040457]; [@b21-0040457]; [@b22-0040457]; [@b83-0040457]; [@b115-0040457]). The complete absence of functional Smn, which never occurs in patients, suggests that these models provide only limited insights into the pathogenesis of SMA; however, the absence of convincing data regarding whether complete ablation of full-length Smn is achieved at a range of time points precludes a definitive judgment. A more recently published study in which endogenous Smn was conditionally depleted in motor neuron progenitor cells, but importantly was not totally ablated owing to the presence of transgenic human *SMN2*, provides a potentially better model of the disease ([@b86-0040457]). However, the presence of normal levels of Smn in tissues other than motor neurons seems to result in an unexpectedly mild phenotype, hinting that the SMA phenotype might be more dependent on systemic effects than previously appreciated.

The severe (*SMN2* transgenic) mouse and its modification, the SMNΔ7 mouse, have become the most widely used SMA models ([Fig. 1](#f1-0040457){ref-type="fig"}). In the remainder of this Perspective, we discuss how these and other mouse mutants have been used to address important outstanding biological questions about SMA. We begin by examining whether SMA is neurodegenerative or neurodevelopmental in its essential character, and then move on to discuss the evidence for absolute or relative motor neuronal specificity in SMA, as well as the timing of SMN protein action during development. Finally, we examine the controversy about whether SMA is a disorder of splicing regulation or whether SMN has a distinct neuronal function.

The nature of SMA: neurodegeneration or failure of normal development?
======================================================================

The commonest and most severe form of SMA (Type I; previously known as Werdnig-Hoffmann disease) begins prenatally or in the early postnatal period, during a time of maturation and stabilization of the neuromuscular system, the basic pattern of which is laid down earlier in development. By contrast, the onset of muscle weakness in at least some cases of other forms of SMA (late-childhood and adult-onset SMA) occurs after the neuromuscular system has developed. Nevertheless, in these later-onset patients it remains possible that the foundation for subsequent loss of neuromuscular integrity and subsequent age-dependent motor neuron degeneration is established in earlier development.

###### 

Mouse models of SMA

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Genotype**                                                                    **Severity of phenotype[^a^](#tfn1-0040457){ref-type="table-fn"}**   **Notes**                                                                                                                                                                   **References**
  ------------------------------------------------------------------------------- -------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------
  *Smn*^−/−^                                                                      ++++                                                                 Death of embryo occurs prior to uterine implantation.                                                                                                                       ([@b102-0040457])

  *Smn*^+/−^                                                                      \+                                                                   Early acute loss of lumbar spinal cord motor neurons (∼28% within 5 weeks), with subsequent slowly progressive reduction over an extended time scale.                       ([@b46-0040457]; [@b6-0040457])

  *Smn*^−/−^; *SMN2(2Hung)*^+/+^                                                  \+ to +++                                                            Transgene including human *SMN2*, *SERF1* and part of *NAIP*; rescues embryonic lethality of *Smn*^−/−^.\                                                                   ([@b43-0040457])
                                                                                                                                                       Transgene copy number correlates with disease severity, which ranges from death within 1 week to normal survival.                                                           

  *Smn*^−/−^; *SMN2(89Ahmb)*^+/+^                                                 \+ to +++                                                            Transgene containing only the *SMN2* locus, rescues *Smn*^−/−^ embryonic lethality.\                                                                                        ([@b77-0040457])
                                                                                                                                                       42/56 mice with one or two transgene copies were stillborn or died before 6 hours, with the remainder dying between 4--6 days.\                                             
                                                                                                                                                       Mice with eight copies of the transgene reach adulthood.                                                                                                                    

  *Smn^F7/Δ7^*; *NSE-Cre*^+^                                                      ++                                                                   *Smn^F7/Δ7^* mice with Cre-*loxP*-mediated deletion of *Smn* exon 7 in neuronal tissue.\                                                                                    ([@b35-0040457]; [@b22-0040457])
                                                                                                                                                       Mean lifespan: 25 days.                                                                                                                                                     

  *Smn^F7/Δ7^*; *HSA-Cre^+^*                                                      ++                                                                   *Smn^F7/Δ7^* mice with Cre-*loxP*-mediated deletion of *Smn* exon 7 in myoblasts and post-mitotic fused myotubes of skeletal muscle.\                                       ([@b21-0040457])
                                                                                                                                                       Mean lifespan: 33 days.                                                                                                                                                     

  *Smn*^+/−^; *Gemin2*^+/−^                                                       \+                                                                   Mice with heterozygous deletion of *Smn* and *Gemin2* display an accelerated loss of motor neurons compared with *Smn*^+/−^ mice.                                           ([@b48-0040457])

  *Smn*^−/−^; *SMN2(89Ahmb)*^+/−^; *SMN1(A2G)*^+/−^                               \+                                                                   Mean survival of mice with a single *A2G* transgene and one copy of *SMN2* is 227 days, whereas mice homozygous for *A2G* are relatively indistinguishable from controls.   ([@b78-0040457])

  *Smn^F7/F7^*; *HSA-Cre^+^*                                                      \+                                                                   *Smn^F7/F7^* mice with Cre-*loxP*-mediated deletion of *Smn* exon 7 in post-mitotic fused myotubes of skeletal muscle.\                                                     ([@b83-0040457])
                                                                                                                                                       Without heterozygous deletion of *Smn* exon 7 in all somatic cells, animals live for a median of 8 months.                                                                  

  *Smn^F7/F7^*; *NSE-Cre^+^*                                                      ++                                                                   *Smn^F7/F7^*mice with Cre-*loxP*-mediated deletion of *Smn* exon 7 in neuronal tissue.\                                                                                     ([@b29-0040457])
                                                                                                                                                       Mean lifespan: 31±2 days.                                                                                                                                                   

  *Smn^F7/F7^*; *Alfp-Cre*^+^                                                     ++++                                                                 *Smn^F7/F7^* mice with Cre-*loxP*-mediated deletion of *Smn* exon 7 in hepatocytes.\                                                                                        ([@b115-0040457])
                                                                                                                                                       Causes late embryonic lethality at E18.\                                                                                                                                    
                                                                                                                                                       Heterozygous deletion has no obvious effect.                                                                                                                                

  *Smn*^−/−^; *SMN2(89Ahmb)*^+/+^; *SMNΔ7*^+/+^                                   +++                                                                  Transgene containing human *SMNΔ7*, the predominant isoform produced by *SMN2*; improves the phenotype of *Smn*^−/−^; *SMN2*^+/+^.\                                         ([@b59-0040457])
                                                                                                                                                       Mean lifespan: 13.3±0.3 days.                                                                                                                                               

  *Smn*^−/−^; *SMN2*^+/+^; *SMN1(A111G)*^+/−^                                     \+                                                                   Transgene containing the *SMN1* allele seen in Type I and II patients; improves survival to over 1 year with no obvious phenotype.                                          ([@b121-0040457])

  *Smn*^−/−^; *SMN2*^+/+^; *SMN1(VDQNQKE)*^+/−^                                   +++                                                                  Transgene containing *SMN1* exons 1--6 with an additional motif; has little effect on lifespan extension.                                                                   ([@b121-0040457])

  *Smn*^*2B*/−^                                                                   ++                                                                   *Smn* transgene harboring three nucleotide substitutions within the exonic splicing enhancer of exon 7.\                                                                    ([@b12-0040457])
                                                                                                                                                       Mean lifespan: 28 days.                                                                                                                                                     

  *Smn*^−/−^; *SMN2(N11)*^+/−^; *SMN2(N46)*^+/−^                                  +++                                                                  Mice with three copies of *SMN2* were generated by crossing strains with two (N11) and four (N46) copies.\                                                                  ([@b75-0040457])
                                                                                                                                                       Mean lifespan: 15.2±0.4 days.                                                                                                                                               

  *Smn*^*F7*/−^; *SMN2(89Ahmb)*^+/+^; *Olig2-Cre*^+^                              \+                                                                   *Smn*^*F7*/−^; *SMN2*^+/+^ mice (i.e. *Smn*^+/−^; *SMN2*^+/+^) with Cre-*loxP*-mediated deletion of *Smn* exon 7 in spinal cord motor neuron progenitor cells.\             ([@b86-0040457])
                                                                                                                                                       ∼70% of mutants survived to 12 months, yet were clearly distinguishable from controls.                                                                                      

  *Smn1^tm1Cdid/tm1Cdid^*; *Cre^Esr1^* and *Smn1^tm2Cdid/tm2Cdid^*; *Cre^Esr1^*   ++++                                                                 Inducible *Smn* alleles that mimic *SMN2* splicing are homozygous embryonic lethal (E12.5--E15.5) and normal when heterozygous.\                                            ([@b40-0040457])
                                                                                                                                                       In the presence of Cre recombinase, *loxP*-flanked *neomycin* (*Neo*) gene resistance cassettes situated in *Smn* intron 7 are excised, producing full-length Smn.\         
                                                                                                                                                       When crossed with a tamoxifen-inducible *Cre* allele (*Cre^Esr1^*), early embryonic induction of full-length *Smn* by tamoxifen can rescue embryonic lethality.             
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

+, mild; ++, moderate; +++, severe; ++++, embryonic lethal.

Smn^F7/Δ7^ mice are Smn^+/Δ7^, and Smn^F7/F7^ mice are Smn^+/+^.

![**Timeline illustrating the major cellular and symptomatic events during the embryonic and postnatal development of severe (*Smn*^−/−^; *SMN2*^+/+^) and SMNΔ7 (*Smn*^−/−^; *SMN2*^+/+^; *SMNΔ7*^+/+^) mouse models of SMA.** MN, motor neuron; NF, neurofilament; NMJ, neuromuscular junction; SC, spinal cord; snRNP, small nuclear ribonucleoprotein; TVA, transversus abdominis.](DMM007245F1){#f1-0040457}

Primary motor neurons isolated from the lumbar spinal cord of severe SMA mouse embryos at embryonic day 14 (E14) do not show reduced survival in culture, but axon elongation, growth-cone size, β-actin dynamics and spontaneous excitability are all significantly impaired ([@b97-0040457]; [@b50-0040457]). A similar phenotype has also been observed in cultured sensory neurons ([@b49-0040457]). Moreover, differentiation and neuritogenesis, but not survival or growth, of neurospheres from the brains of severe SMA mouse embryos is abnormal ([@b104-0040457]). However, direct neurophysiological recording from Smn-deficient mouse motor neurons in culture does not show a functional deficit ([@b123-0040457]).

In contrast to the above observations from in vitro systems showing abnormalities in embryonic motor neurons, the available SMA mouse models have similar numbers of motor neurons in the spinal cord at birth compared with their control littermates, and are visibly indistinguishable from these mice, suggesting that gross prenatal development is largely unaffected by Smn depletion ([@b43-0040457]; [@b77-0040457]; [@b59-0040457]). No major defects in axonal morphology or outgrowth were seen at various embryonic stages in multiple different tissues of severe mutants expressing GFP in motor neurons (Hb9-SMA mice) ([@b70-0040457]). There was, however, a significant increase in the number of vacant synapses lacking motor axon input at E18 in intercostal muscles ([@b70-0040457]), and neuromuscular junction (NMJ) neurofilament accumulation and an increased length of axon terminals was observed in the phrenic nerve of SMNΔ7 mice at E18.5 ([@b52-0040457]). Nonetheless, in a detailed study of the NMJ in severe SMA mice at a pre-symptomatic stage (P1), there were no detectable defects in motor axon patterning and branching, NMJs were formed normally, and there were no significant changes in gene expression in the spinal cord ([@b81-0040457]).

Disruption of the NMJ is known to occur in a range of different muscles during early and late symptomatic stages in postnatal severe SMA mice ([@b80-0040457]). Neuromuscular pathology was found to be more pronounced in the predominantly slow-twitch transversus abdominis muscle as well as the caudal band of the fast-twitch levator auris longus in these mice ([@b79-0040457]; [@b100-0040457]), suggesting differential vulnerability of NMJs, which has also been observed between the diaphragm and soleus ([@b116-0040457]). Similar progressive postnatal neuromuscular pathology has been observed in a new SMA model that carries three copies of *SMN2* ([@b75-0040457]) and in the SMNΔ7 mouse ([@b51-0040457]; [@b79-0040457]; [@b57-0040457]), although the majority of pathology observed in SMNΔ7 mice resulted in modified neurofilament accumulation and functional disruption at the NMJ rather than loss of presynaptic motor nerve terminals. These presynaptic changes occurred in tandem with a delay in developmental maturation of postsynaptic acetylcholine receptors ([@b10-0040457]; [@b51-0040457]; [@b57-0040457]). Alongside these morphological and functional changes at the NMJ, longitudinal exon-level gene-expression studies in the spinal cord of the SMNΔ7 model showed an apparent failure of expression of genes that cluster in postnatal developmental pathways ([@b7-0040457]).

If SMN has distinct functions during the period of postnatal neuromuscular development, this would have profound implications for the timing of SMN replacement therapy. Observations in mouse models of SMA suggest that NMJs can form and function normally prior to the postnatal onset of disease ([@b81-0040457]), and that NMJ denervation precedes motor neuron loss ([Fig. 1](#f1-0040457){ref-type="fig"}) ([@b51-0040457]; [@b79-0040457]; [@b57-0040457]). Thus, the high levels of SMN seen during early postnatal development, the window of developmental vulnerability to SMN depletion and the perinatal onset of severe SMA all suggest that the disease is related to postnatal maturation events in the neuromuscular system ([@b7-0040457]; [@b81-0040457]).

Is motor neuron specificity in SMA absolute or relative?
========================================================

In contrast to evidence from mouse models of severe SMA, severe infantile SMA in patients carrying only one or two copies of *SMN2* can begin in utero and can be associated with extended involvement of the peripheral nervous system, including demyelination, inexcitability and axonal degeneration in sensory neurons ([@b58-0040457]; [@b85-0040457]; [@b98-0040457]; [@b1-0040457]). Moreover, it has been recognized by neuropathologists for many years that specific regions of the brain such as the thalamus show neuronal loss in severe SMA patients, although this has been assumed to be subclinical ([@b107-0040457]; [@b122-0040457]; [@b84-0040457]; [@b41-0040457]; [@b3-0040457]; [@b45-0040457]).

The first major study of the involvement of non-motor nervous tissue in SMA in mice reported that cell body size and number in dorsal root ganglia (DRG) were normal, even at the late symptomatic stage (P5) in the severe model, but that sensory neurons cultured from E14 embryos showed reduced neurite length and growth-cone size ([@b49-0040457]). Nerve endings from E14 SMA mouse embryo footpads were much thinner than those of controls and failed to reach their target destination in the outer epidermal layer, although without displaying a difference in number. Consistent with this, the latency to paw withdrawal in a hot plate test was increased more than twofold in a new severe model ([@b75-0040457]). In the SMNΔ7 mouse, no defect in tactile sensory behavior was seen at early to mid disease stages, as assessed by the clasping of paws in response to gentle stimulation ([@b17-0040457]). Recently, sensory and motor synapses were examined in Olig2-Cre mice (mild SMA model), which have selectively depleted Smn levels in motor neuron progenitor cells ([@b86-0040457]). By staining sensory nerve terminals of the DRG, the authors showed that adult mutant mice had a reduction in the number and the mean area of synaptic boutons positioned against cholinergic motor neurons. These defects were present by P7, indicating that dysfunction in sensory neuronal projection onto ventral horn cells develops at early stages of the disease. Central synaptic defects that precede motor neuron loss have also recently been reported in the spinal cord of SMNΔ7 mice by P4 ([@b62-0040457]; [@b73-0040457]), which were more severe in proprioceptive inputs onto motor neurons innervating proximal muscles ([@b73-0040457]). Olig2 expression is confined to spinal motor neurons and oligodendrocytes, so the sensory neuron defects seen in this Cre-*loxP* mouse model are unlikely to be caused by Smn depletion in DRG proprioceptive neurons, and are perhaps a direct consequence of pathological mechanisms triggered within the motor neurons ([@b86-0040457]). In addition to affecting motor and sensory neurons, it appears that Smn reduction also affects neuritogenesis and neurogenesis in the retinal neurons of *Smn*^*2B*/−^mice ([@b64-0040457]).

Pathological changes in the brain have also been studied in severe SMA mice. Increased cell death was observed in the forebrain of E14.5 mutant embryos, with the telencephalon being the most severely affected ([@b63-0040457]). This cell death was independent of genetic background and was associated with a greater than 70-fold increase in the amount of irregular nuclei. Striking pathological foci of hyperchromatic cells containing cell debris and condensed or shrinking nuclei were also observed. As expected, cell death in the telencephalon was less severe at earlier embryonic stages. Reduced Smn expression has also been shown to affect perinatal development of the mouse brain, with a lower brain weight and size at late symptomatic but not pre-symptomatic stages ([@b120-0040457]). Interestingly, morphology varied between different brain regions, suggesting a gradient of susceptibility to Smn deficiency and not merely an overall reduction in brain volume as a reflection of smaller body size. The primary motor cortex displayed a subtle progressive decline in size from birth, whereas the primary somatosensory cortex remained unaffected at all stages studied. The most striking defects were observed in the hippocampus: a 50% reduction in the size of the dentate gyrus in late-symptomatic SMA mice compared with controls was associated with a reduction in cell density, cell proliferation and postnatal neurogenesis ([@b120-0040457]). Proteomic analysis of the hippocampus of SMA mice revealed numerous changes in the expression of proteins involved in the regulation of cell proliferation, growth, migration and development ([@b120-0040457]). Notably, a microarray study has also identified deficits in normal proliferative pathways in the spinal cord of severe SMA mice, perhaps accounting for the reduced number of proliferating cells in the central canal of the spinal cord ([@b7-0040457]). Together, these studies implicate cellular proliferation and postnatal developmental pathways in the pathogenesis of SMA in both motor and non-motor regions of the nervous system.

The presence of non-motor abnormalities in severe forms of SMA suggests that there is a gradient of susceptibility to SMN reduction in the nervous system, with motor neurons at one end of a spectrum ([Fig. 2](#f2-0040457){ref-type="fig"}). These observations, coupled with evidence from mouse models indicating that dysfunction in non-neuromuscular tissue might also contribute to the overall pathology of SMA, have led to the development of the threshold hypothesis (Box 1). An important consequence of this work is that it clearly indicates that therapies aimed at replacing SMN, either by gene delivery or by oligonucleotide-mediated alterations in *SMN2* splicing, should be delivered systemically. Although it is currently only a theoretical concern, it is possible that the correction of motor neuron loss and subsequent improved survival would reveal effects on other regions of the central nervous system (CNS) and other organs in the long term, with major clinical consequences.

Is SMN a general survival factor for motor neurons?
===================================================

Complete absence of SMN is lethal to all cells, but it remains unclear whether SMN is required at the same levels, and at all stages of development, in different cell types. Similarly, it remains unknown whether SMN levels are required to be above a critical threshold for motor neuron survival in adult life. If replacing SMN levels after a specific developmental time point would have little or no effect on the trajectory of disability, this has major implications for the optimization of SMA therapy. Similarly, it is important to understand whether therapies must achieve a maintenance level of SMN into adulthood to preserve neuromuscular integrity in the face of normal aging. Furthermore, if SMN can act as a survival factor for motor neurons in adult life, it might serve as a therapeutic target for other neuromuscular diseases, including amyotrophic lateral sclerosis (ALS).

The onset of SMA is not infrequently reported to be rather sudden, occurring over a period of days to weeks. Rapid decline in motor function is then followed by a long period in which disease progression is relatively slow ([@b111-0040457]). A similar phenomenon has been reported in the Olig2-Cre SMA mice, in which Smn is selectively depleted in motor neurons ([@b86-0040457]). Although at birth these mice are indistinguishable from controls, mutants rapidly develop functional defects in the first week of life, some of which seemed to stabilize with age. These periods of rapid, progressive decline with subsequent relative stability suggest that there is a specific period of development during which SMN depletion is most detrimental to motor function. Consistent with this, Smn in the mouse is most highly expressed in spinal cord and brain during embryonic and neonatal development, after which time the levels are rapidly reduced and then maintained at a residual level throughout life ([@b36-0040457]). This mimics the situation in humans, in which expression levels of SMN are high in fetal tissue compared with in postnatal periods ([@b16-0040457]).

Delivery of SMN using self-complementary adeno-associated virus 9 (scAAV9) at different developmental stages in SMNΔ7 mice had little effect when administered at P10, and only marginally increased survival when administered at P5. However, when administered at P1, there was an unprecedented improvement in lifespan to over 250 days at the time that the study was submitted for publication, indicating that earlier Smn replacement leads to better survival ([@b33-0040457]). This could be explained either by a higher level of motor neuron transduction efficiency in P1 mice compared with older mice ([@b32-0040457]) or by the effect of increased Smn levels being heavily dependent on the stage of development. Other studies in which compounds have been delivered at different stages support the latter view ([@b82-0040457]; [@b18-0040457]), as does the recent finding that early but not late embryonic restoration of Smn using two inducible *Smn* alleles can rescue lethality ([@b40-0040457]).

Interestingly, mouse models of differing severities show similar degrees of motor neuron loss, perhaps indicating that the developmental stage at which degeneration occurs is a key determinant of disease progression. For instance, compared with controls, severe SMA mice display an approximate 40% reduction in spinal cord motor neuron number at P5, the late-symptomatic stage ([@b77-0040457]), whereas *Smn* heterozygotes display a 40% loss at 6 months and a 54% loss at 1 year ([@b46-0040457]). In a subsequent study of the heterozygous mice, a reduction of lumbar motor neurons by 28% was reported at 5 weeks and by 30% at 3 months, suggesting once again that there is an early period of susceptibility in which there is greater degeneration of motor neurons, followed by a period of relative stability ([@b6-0040457]).

The comparatively high SMN protein levels in the spinal cord during development and the apparent onset of SMA during a restricted perinatal period suggest that the requirement for SMN is temporally regulated in the nervous system. Nevertheless, there is also evidence that SMN might exert positive effects on survival later in life. Significant loss of facial and spinal motor neurons in *Smn*-null heterozygotes has been observed to occur between 6 and 12 months ([@b46-0040457]). However, this seems to be subclinical motor neuron loss, in keeping with the lack of a phenotype in 1 in 40 SMA carriers (those who only carry one copy of *SMN1*) in the general human population ([@b90-0040457]).

![**The threshold hypothesis of SMA.** There seems to be a differential susceptibility of cell types and tissues to SMN reduction. Motor neurons are most severely affected by SMN depletion and are thus at one end of a vulnerability-resistance spectrum. As protein levels are further reduced, additional tissues such as bone, heart and sensory neurons become affected, while other cells and tissues remain unaffected. For example, at approximately 10--20% of normal SMN levels, as seen in Type I SMA patients, motor neurons are severely affected, the heart and brain CNS show partial involvement, whereas many organs remain relatively unaffected. See [Box 1](#box1){ref-type="boxed-text"} for details.](DMM007245F2){#f2-0040457}

A reduction in Smn levels by 50% has also been shown to worsen motor performance and survival of the SOD^G93A^ mouse model of ALS, suggesting that SMN might indeed be constitutively required throughout life ([@b112-0040457]). Furthermore, increasing SMN levels to rescue the severe phenotype in early life has not consistently prevented the ultimate development of a phenotype and a reduced overall lifespan ([@b74-0040457]; [@b87-0040457]; [@b113-0040457]; [@b26-0040457]; [@b88-0040457]).

Is SMA a disorder of splicing regulation?
=========================================

The best-characterized function of SMN is the assembly and processing of snRNPs. The SMN complex, which includes Gemins 2--8 and Unrip, ensures the specific and efficient assembly of a stable heptameric ring of Sm proteins (forming the Sm core) onto newly exported small nuclear ribonucleic acids (snRNAs) ([@b91-0040457]). After further maturation steps, the resulting snRNPs are exported into the nucleus and function in the removal of introns from pre-mRNA transcripts in the process of splicing ([@b93-0040457]). Depending on the class of intron removed, there are two principal types of spliceosomal snRNP that are assembled by the SMN complex: those found in the major spliceosome, which processes almost all eukaryotic introns, and those that splice all other introns as part of the minor spliceosome ([@b89-0040457]). Mouse models provide an opportunity to address the hypothesis, developed from in vitro studies, that snRNP assembly is the crucial function of SMN that is relevant to the pathogenesis of SMA.

The central role of SMN in such a fundamental cellular process provides an adequate explanation as to why complete absence of the protein is universally lethal. Why reduced SMN levels cause such a specific effect on lower motor neurons remains the central conundrum of SMA research. It is possible that motor neurons have a greater constitutive requirement for snRNP assembly and are thus more susceptible to defects in splicing, or that disturbed splicing of a subset of neuron-specific genes triggers motor neuron loss. Alternatively, SMN might have a distinct motor-neuron-specific function, as suggested by the presence of SMN in protein complexes in the axon that have a different makeup than the canonical SMN complex that is involved in snRNP assembly ([@b13-0040457]; [@b96-0040457]).

The evidence for a tight linkage between SMA and functional impairment of snRNP assembly is significant but as-yet incomplete. SMA-causing *SMN1* mutations have been shown to affect the interaction of SMN with Sm proteins ([@b15-0040457]; [@b92-0040457]), and snRNP assembly activity is reduced in SMA patient cells to an extent that is proportional to SMN levels ([@b117-0040457]; [@b37-0040457]). The first study to demonstrate a direct link between snRNP biogenesis and SMA pathology showed that defects in *Xenopus laevis* or zebrafish embryos that were caused by a reduction of SMN or Gemin2 can be rescued by injection of purified snRNPs ([@b119-0040457]). However, a number of SMA-causing *SMN1* mutations, including one found in a Type I SMA patient, display no defect in snRNP assembly activity ([@b108-0040457]) and, despite impairment of snRNP synthesis, endogenous snRNP and snRNA levels were found to be unaltered in patient-derived (Type I SMA) fibroblasts, a chicken cell line and a severe *Drosophila* mutant, all of which had severely reduced SMN levels ([@b117-0040457]; [@b37-0040457]; [@b94-0040457]). Moreover, despite a significant difference in lifespan between the severe and SMNΔ7 models (∼9 days), there is no difference in snRNP assembly activity ([@b37-0040457]), suggesting that the difference in disease severity is caused by differential effects on an additional function of the Smn protein. It should be noted that snRNAs that are not associated with Sm cores are unstable ([@b101-0040457]), so snRNA levels are similar to snRNP levels.

###### The involvement of non-neuromuscular tissue in SMA and the threshold hypothesis

There is evidence that cells and tissues outside of the nervous system are also affected in SMA. Bone and heart complications have been reported in numerous patients (Finsterer and Stöllberger, 1999; [@b53-0040457]; [@b27-0040457]; [@b56-0040457]; [@b5-0040457]; [@b55-0040457]; [@b99-0040457]). Poor perfusion and autonomic dysfunction have also been observed ([@b2-0040457]; [@b39-0040457]; [@b4-0040457]). A similar picture is beginning to emerge in mouse models. SMN has recently been implicated in bone remodeling and skeletal pathogenesis in the severe model ([@b105-0040457]; [@b106-0040457]), which, along with the SMNΔ7 mouse, also displays cardiac defects including bradycardia and arrhythmia ([@b9-0040457]; [@b42-0040457]; [@b103-0040457]). Furthermore, numerous models display a vascular necrosis of the extremities ([@b43-0040457]; [@b74-0040457]; [@b38-0040457]; [@b44-0040457]; [@b75-0040457]; [@b95-0040457]), and the vagus cranial nerve in the severe mouse appears defasciculated, with less distinct morphological boundaries ([@b63-0040457]). The pathological findings in cells other than motor neurons, which are predominantly seen in more severe cases, have led to the development of the threshold hypothesis. This hypothesis proposes that there is a differential susceptibility of cells to SMN depletion ([Fig. 2](#f2-0040457){ref-type="fig"}), and that different cell types and tissues fall in different positions within a vulnerability-resistance spectrum. At one extreme, motor neurons seem to be the most sensitive cell type to reduced SMN levels. As SMN levels are further reduced, the range of affected cells becomes greater, to a point at which there is insufficient protein for survival of any cell type. It is thus important that protein levels in animal models of SMA do not reach the threshold at which there is universal cell degeneration, because such a model will not be useful for dissecting the reasons why motor neurons are particularly vulnerable. Together, these findings suggest that SMA is a multisystem disorder; this has great significance for the development of new treatments, because therapies will need to be delivered systemically for the greatest chance of success. Moreover, improved understanding of this differential susceptibility is likely to offer further insights into the function of SMN in neurons.

Steady-state snRNA levels in spinal cord extracts of 3-day-old severe SMA mice are also only marginally reduced in spite of a tenfold decrease in snRNP assembly activity ([@b37-0040457]). This apparent contradiction indicates that cells possess an excess capacity to assemble snRNPs, such that reducing SMN levels has only a modest effect. However, levels of a subset of snRNAs belonging to the minor splicing pathway (U11 and U12) were significantly reduced in the brain and spinal cord of severe SMA mice ([@b37-0040457]). U11 snRNA levels were also lowered in the kidney, suggesting that reduced SMN levels can unevenly affect the profile of snRNPs in a tissue-specific manner. This preferential reduction in minor snRNAs in the context of reduced SMN levels has since been confirmed in a number of different models and tissues ([@b124-0040457]; [@b121-0040457]).

The correlation between disease severity and snRNP assembly activity has been shown in a range of mouse models ([@b37-0040457]; [@b121-0040457]). In mouse spinal cord, snRNP biogenesis is most prominent in the CNS during embryogenesis and early postnatal development, correlating with levels of Smn ([@b36-0040457]). The spatiotemporal expression patterns of Smn and Gemin2 are closely co-regulated, and the subclinical motor neuron loss seen in *Smn* heterozygous mice is accelerated in *Smn*^+/−^; *Gemin2*^+/−^ heterozygotes, which is associated with a reduction in snRNP assembly ([@b47-0040457]; [@b48-0040457]).

It is clear that the formation of snRNPs is affected by SMN reduction. However, the functional consequences of this disturbed assembly and how this contributes to SMA pathology are much less clear. If a failure of snRNP assembly is the pathological lesion that leads to selective motor neuron death, this would be predicted to cause dysfunctional splicing across a wide range of pre-mRNA transcripts at or before disease onset, and also to result in 'aberrant' transcripts that are not normally seen in tissues in physiological states. However, there is only an approximately twofold increase in the error rate of splice-site pairing in phenotypically normal fibroblasts from severe Type I SMA patients ([@b34-0040457]). In end-stage (P13) SMNΔ7 mice, Zhang et al. used exon-level microarrays to identify widespread tissue-specific splicing abnormalities, even in histologically normal tissues such as the kidney ([@b124-0040457]). This curious finding suggests a lack of congruence between splicing abnormalities and cellular pathology, and, given that the mice assayed were moribund, might simply reflect a non-specific response to tissue injury. A longitudinal study of exon-level changes in the spinal cord of both severe and SMNΔ7 mice at pre-symptomatic (P1), early-symptomatic (P7) and late-symptomatic (P13) stages suggests that the vast majority of alternative splicing events are actually a late feature of disease and are thus unlikely to play a causative role in SMA pathology ([@b7-0040457]). Only a small number of transcripts were altered compared with control mice at the pre-symptomatic stage, and all alterations involved a shift to known isoforms. Additionally, the introns processed by the minor spliceosome were not preferentially affected, as might be expected if the specific reduction of minor spliceosomal snRNPs had a direct effect on splicing. The role of the small number of genes that are alternatively spliced early on in the disease, and a possible axon-specific function for SMN, should be further assessed in SMA mouse models.

Conclusions
===========

SMA is a devastating disorder of the nervous system that predominantly affects very young children and has no available treatment. A number of key questions about causative pathways and disease pathology remain unresolved, and their clarification will help both to improve our general understanding of the disease mechanism but also crucially inform the development and optimization of novel therapeutic strategies. An abundance of studies have demonstrated that multiple mouse SMA models that mimic the broad spectrum of disease seen in patients and that allow conditional SMN expression are required to fully explore these complex issues. Owing to the great progress in furthering our basic biological understanding of SMA and the availability of appropriate preclinical models, this disease has been highlighted by the NIH and other funding bodies as being one of the neurogenetic diseases that is closest to being cured. A wide range of different therapeutic approaches -- including viral-mediated gene delivery, small molecules that upregulate SMN expression, and oligonucleotide-mediated splicing modification -- are now close to entering clinical trials. As these therapies approach clinical translation there will still be much to learn from mouse models about how to best apply these therapies for the benefit of patients.
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